Research programme: AAV/ZFP TF pain therapy - Avigen/Sangamo Therapeutics

Drug Profile

Research programme: AAV/ZFP TF pain therapy - Avigen/Sangamo Therapeutics

Alternative Names: AAV/ZFP TF

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avigen; Sangamo BioSciences
  • Class
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 08 Jan 2007 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
  • 10 Jun 2004 A preclinical study has been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top